Myeloma News and Research

RSS

Combination of drugs amplifies kill rates of brain cancer tumours in mice

A promising combination of immunotherapies delivers a one-two punch to brain cancer tumours with high cure rates in mice, scientific evidence published in Nature Communications today says.

15 Feb 2017

Researchers discover new culture method that unlocks natural fighter function of immune T cells

Mayo Clinic and University of Washington researchers have discovered a new culture method that unlocks the natural fighter function of immune T cells when they are passing through the bloodstream.

14 Feb 2017

Professor aims to develop shortcuts for targeted and effective cancer therapy

The aim is to identify precisely the one drug, or the correct combination of drugs, that are most effective against the specific tumor present in each patient. Professor hopes that new tools will come into use in the next five years.

13 Feb 2017

New NCCN patient guide for Waldenström's Macroglobulinemia helps make informed treatment decisions

A very rare sub-type of Non-Hodgkin's Lymphoma, Waldenström's Macroglobulinemia affects approximately 1,500 - 2,000 people in the United States each year. While it is not curable, Waldenström's Macroglobulinemia is slow growing, and in many patients, manageable as a chronic disease.

6 Feb 2017

Inhibition of EZH2 protein could be new strategy to treat multiple myeloma

In a study published in the scientific journal Oncotarget, researchers from Uppsala University show how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease.

12 Jan 2017

Epigenetic modification may be cause of adult throat cancers linked to alcohol, tobacco use

A team of researchers at the Research Institute of the McGill University Health Centre has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use.

12 Jan 2017

NCCN publishes new easy-to-understand patient education resources focused on brain cancer

The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer - Gliomas—the first in a series of patient education resources focused on Brain Cancer.

10 Jan 2017

Whitehead Institute researchers identify mechanism underlying cancer drug-resistance

The use of proteasome inhibitors to treat cancer has been greatly limited by the ability of cancer cells to develop resistance to these drugs.

27 Dec 2016

Study shows three-drug combination delays recurrence and lengthens life for myeloma patients

The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.

23 Dec 2016

Researcher develops new method to accurately identify elusive molecules

Among the most important molecules in the living world are sugars or carbohydrates, which play a vital role in life processes. Sugars provide the main source of fuel for the body, protect muscles from damage and contribute to the immune response.

21 Dec 2016

Defective ribosomes linked to aggressive form of multiple myeloma

20 to 40 percent of the patients with multiple myeloma - a type of leukaemia - have a defect in the ribosome, the protein factory of the cell.

9 Dec 2016

Personalized cancer vaccine improves outcomes for patients with AML, clinical study shows

A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center.

9 Dec 2016

Additions to standard therapy do not improve progression-free survival in patients with multiple myeloma

Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.

6 Dec 2016

Clonal hematopoiesis may help predict cancer patients at risk for fatal form of leukemia

Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).

4 Dec 2016

Maintaining healthy weight may be key to prevent MGUS progression to multiple myeloma

New research shows that excess weight increases the risk that a benign blood disorder will progress into multiple myeloma, a cancer of the blood.

18 Nov 2016

Yale researchers develop new mouse model to understand multiple myeloma

Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine.

21 Oct 2016

Houston Methodist researcher receives $4 million to create triple negative breast cancer immunotherapy

Scientists at Houston Methodist received support from the U.S. Department of Defense to reprogram cancer patients' immune cells to attack triple negative breast cancer, the most lethal form of breast cancer.

13 Oct 2016

NCCN publishes new resources to help patients understand treatment options for stomach cancer

This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year.

4 Oct 2016

Blood cancer treatment linked to distinct increase in molecular age of immune cells

Certain cancer treatments are known to take a toll on patients, causing side effects like fatigue, nausea and hair loss. Now, scientists are investigating whether some treatments can cause another long-term side effect: premature aging of important disease-fighting cells.

1 Sep 2016

Added benefit not proven for new combination therapy in multiple myeloma

The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment.